In this study we have investigated five quantitative and three semi-quantitative rheumatoid factor assays and the Rose-Waaler assay in 120 patients suffering from rheumatoid arthritis and in 76 with other systemic diseases. All tests measure the IgM anti-IgG antibodies.
Introduction
The measurement of rheumatoid factors in patients with rheumatoid arthritis can provide information about the diagnosis, prognosis and response to therapy of the disease.
The rheumatoid factors are äütoantibodies against the Fc fragment of the immunoglobulin G (IgG).
The antibodies measured in most laboratory assays are of the IgM class, although they also appear in other immunoglobulin classes (1) .
The classical method for the determination of the rheumatoid factors is the Rose-Waaler haemagglutination assay (2, 3) .
This semi-quantitative dilution assay is difficult to standardize, has a poor reproducibility and is rather laborious.
To overcome some of these problems, we have used for several years a modified Rose-Waaler assay in our laboratories (4) .
Recently several new automated analysers and techniques for the quantitative determination of rheumatoid factors have become available.
They consist of radio-(5) and enzyme-immunoassays (6), or nephelometric (7) and turbidimetric methods (8, 9) .
In this study we describe an evaluation of five quantitative rheumatoid factor assays, one semi-quantitative latex test and two modified Rose-Waaler assays. These tests all measure the IgM anti-IgG antibodies.
The results are compared with those determined with the traditional Rose-Waaler method. 
Patient samples
The samples were obtained from patients visiting the rheumatology and pulmonary departments of our hospitals (tab. 2).
The diagnosis, rheumatoid arthritis, was obtained by the rhetimatologists using the American Rheumatism Association criteria (10) .
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The blood samples were collected by venepuncture in vacutainer SST tubes (Becton and Dickinson, Rutherford, NJ, USA) and allowed to clot. The serum was removed and, in order to avoid repeated freezing and thawing, divided into aliquots and stored at -20 °C until assay.
All samples were inactivated by incubating for 30 minutes at 56 °C, except for the method of Diesse Taso-Matic (D) and the RF-tube test (H).
For both Beckman methods, Array (A) and ICS (B), the inactivated samples were centrifuged at 8000 g for five minutes.
Standardisation and controls
For the titration methods the "Relares serum" (the Dutch reference serum preparation for rheumatoid factors related to the "international reference preparation of rheumatoid arthritis serum of the WHO") (11) was used as a standard to convert titres to IU/ml.
For the preparation of this "Relares serum", plasma was first obtained by plasmapheresis from 20 patients with rheumatoid arthritis. Serum was then prepared by recalcification and di- For the five quantitative methods the standard(s) provided with the kits were used. The standard used for the Behring BNA (C), Diesse TasoMatic (D) and Cobas-Bio/Orion (E) is related to the WHO reference serum. For Beckman Array (A) and Beckman ICS (B) the standard is related to the "American Center of Disease Control National Reference Preparation for rheumatoid factors" (12) .
In all semi-quantitative and quantitative assays we used the "Behring Rheumatoid Reference Serum" as a control.
This reference serum consists of a pool of human sera with a high concentration of rheumatoid factors. The reference serum is calibrated according to the Rose-Waaler test as recommended by the WHO (11) by comparison with the WHO International Reference Preparation.
In the quantitative tests we used also the "Relares serum" as a control serum.
Statistical analysis
Orthogonal regression analysis was performed according to the method of Deming as discussed by Cornbleet et al. (13) .
The outlayers test described herein was only used in the correlation analyses of the five quantitative tests (A-E). Outlayers were defined as values outside four times the standard error of estimate (13) .
Precision between and within runs
Precision studies were performed with the following five quantitative methods: Beckman Array (A), Beckman ICS (B), Behring BNA (C), Diesse TasoMatic (D) and Cobas-Bio/Orion (E).
The within fun precision analyses were carried out in pooled patient sera. Each serum was estimated 8 to 12 times. The sera were choosen so that the concentrations of rheumatoid factors were spread over the whole measuring range of the instruments. The value of 499 lU/ml by the Diesse TasoMatic method (D) however was obtained with diluted (9 g/1 NaCl) serum.
For the between run precision analyses we used two to four samples in every run. These samples were Behring Rheumatoid Reference Serum for rheumatoid factors, Relares serum, Pooled Patient Serum, Standard 100 IU/ml of Diesse and Calibration Serum of Beckman.
Correlation studies
The titres of the dilution methods were converted to IU/ml before the regression analyses were performed.
For the correlation studies we used the results of all 196 patients, unless one or both values were zero, below the lowest standard or below the detection limit of the method.
Sensitivity, specificity and predictive value (14) Sensitivity indicates the probability of positive test restults when the disease is present (positivity in disease).
It may be expressed by the following relationship:
number of RA-paticnts with positive test total number of RA-patients Sensitivity = Specificity indicates the probability of negative test results when the disease is not present (negativity in health).
It may be expressed by the following relationship: Specificity _ number of patients without RA with negative test total number of patients without RA
The predictive value of a positive test is expressed by:
number of RA-patients with positive test total number of positive tests
The predictive value of negative test is expressed by:
number of patients without RA with negative test total number of negative tests
The predictive value of a positive (negative) test indicates the probability that the disease (RA, rheumatoid arthritis) is present (absent) when the test is positive (negative).
Results and Discussion

Precision within and between runs
The within and between run precision data are given in table 3.
The within run precision was good (< 4%) for the Beckman Array (A) method, the Behring BNA (B) method (except for the value 575 IU/ml) and the Cobas-Bio/Örion (E) method [except near its detection limit of 15 IU/ml (CV = 16% for the value of 19 IU/ml)].
The coefficient of variation of 8.4% for the Behring BNA (B) method was obtained in a pooled patient serum with a mean value of 575 IU/ml. This value is near the beginning of the range requiring dilution of the sample.
The ten results for this pooled serum are shown in table 4. The mean value for the four undiluted samples was 517 IU/ml and for the six automatically diluted samples 614 IU/ml. This difference in mean values might be explained by the use of different parts of the calibration curve.
For the Diesse TasoMatic (D) the within run precision appeared to be satisfactory with a CV < 11%, taking into account the stepwise presentation of the results. The between run precision for the Beckman Array (A) and the Behring BNA (C) was good (< 9%), for the other quantitative methods acceptable (< 17%).
The manual titre methods gave a maximal difference of only one dilution step.
Correlation studies
The correlations between the quantitative and semiquantitative methods and between the semi-quantitative methods themselves are shown in table 5. The correlation between the quantitative tests themselves is much stronger then between the semi-quarititative and quantitative tests or between the semiquantitative tests themselves.
This less satisfactory coefficient of correlation can be partly explained by the use of titres. In the'conversion of titres to numerical values (lU/ml) a difference of only one dilution step causes the doubling or halving of the value in lU/ml (15 Diesse
For the Cellognost-RF-micro (F), a titre of 1 : 80 corresponded to 400 lU/ml, for the RAHA (G) a titre of 1 : 2560 represented 300 lU/ml, while for the RFtube-test (H) a titre of 1 : 160 represented a value of 200 lU/ml. For the Rose-Waaler method (I) the Relares serum was used as a standard (400 lU/ml) in every run to convert the titres into lU/ml.
In every run also the Behring Rheumatoid Reference serum was assayed. For the Cellognost-RF-Micro (F) a value of 200 lU/ml was found, for the RAHA (G) 50 lU/ml and for the RF-tube test (H) 75 lU/ml.
For the Rose-Waaler method this Behring Rheuma-
Standardisation and controls
Semi-quantitative methods
In order to convert titres to Ill/ml for each method in every run the Relares serum was assayed. After all assays were complete, the mean titre of the Relares serum was compared with its target value in lU/ml (16) .
toid Reference Serum was assayed twice at 100 IU/ ml.
Quantitative methods
Data were first obtained by using the standards supplied with the kits. In addition the Relares Serum and the Behring Rheumatoid Reference Serum were analysed in every run. Table 7 shows the mean values and standard deviations for these two sera. It should be mentioned that the standards used in methods A and Β were related to the reference preparation of the Center of Disease Control, but for the other methods (C, D and E) to that of the WHO. 
118 [10] 90 [10] 76 [8] was a large systematic difference in the actual values found. These differences were observed for the patient sera (tab. 6, figs. 1 and 2) as well as for the Relares Serum and the Behring Rheumatoid Reference Serum (tab. 7).
This discrepancy in bias might be explained by the variability of the IgG antibodies used in the various kits. Another explanation could be the difference in the origin of the rheumatoid factor preparations used as standards in the kits, since these rheumatoid factors are a group of diverse globulins.
We also investigated the number of positive patient sera which exceeded the measuring ranges of the kits. A large difference was found between the methods used; see table 8.
Sera showing values above the upper limit of the measuring range were diluted 1:6. Further dilution was necessary for sixteen of the sera, but only for the Cobas-Bio/Orion method. In table 9 the sensitivity, specificity, the positive and the negative predictive values of the methods used (A -I) are shown.
With regard to these calculations we divided the patients into two groups. The first group consisted of the patients suffering from classical rheumatoid art hritis and definitive rheumatoid arthritis, i.e. numbers one and two ( from table 2. The second group consisted of the patients suffering from other diseases, such as reactive arthritis, sarcoidosis, ankylosing spondylitis, Morbus Reiter and systemic lupus erythematosus, i.e. numbers three to seven from table 2. 
